Treatment for First-Episode Schizophrenia
Public ClinicalTrials.gov record NCT00000374. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Preventing Morbidity in First-Episode Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
Study identification
- NCT ID
- NCT00000374
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 1998
- Primary completion
- Apr 30, 2007
- Completion
- Apr 30, 2007
- Last update posted
- Jan 12, 2012
1998 – 2007
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hillside Hospital | Glen Oaks | New York | 11004 | — |
| Bronx-Lebanon Hospital Center | The Bronx | New York | 10456 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Schizophrenia trials
Other public records listing Schizophrenia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07686263: Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia Recruiting
- NCT07615426: A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia Recruiting
- NCT07788755: NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia Not yet recruiting
- NCT07783373: Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia Active, not recruiting
- NCT07734493: A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia Recruiting
- NCT07772349: Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3) Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00000374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2012 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00000374 live on ClinicalTrials.gov.